What IBSA does

IBSA (Institut Biochimique SA) is a privately held Swiss pharmaceutical company founded in 1945 and headquartered in Lugano-Pazzallo, Switzerland. Since its 1985 acquisition by Arturo Licenziati, the company has grown from a near-bankrupt operation with 40 employees and 6 million CHF in revenue to a multinational group with 2,500+ employees across 20 wholly-owned subsidiaries and a 2022 revenue of 883 million CHF, operating in 90+ countries. Its business spans 10 therapeutic areas — reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, and consumer health — with a particular focus on incremental innovation in drug delivery applied to established active ingredients rather than novel molecule discovery.

IBSA's core competitive layer is its portfolio of proprietary drug delivery platforms: PEARLtec softgel capsule technology (used in Tirosint levothyroxine), FilmTec orodispersible films (used in iron supplements and pharmaceuticals such as sildenafil ODF), NAHYCO hybrid hyaluronic acid complexes (developed with Università Vanvitelli and Altergon Italia), and BoV Bag-on-Valve topical delivery. Manufacturing is vertically integrated, anchored by FDA-approved facilities in Manno (softgel capsules), Lamone (gonadotropin purification, 25 million vials/year, WHO-recognised analytical lab), Collina d'Oro (multi-purpose oral solids), and the 2022 cosmos facility in Lugano (pre-filled syringes, single-dose strips, oral solids), supplemented by Italian sites in Lodi and Cassina de' Pecchi and Chinese operations at Qingdao Huashan Biochemicals and Rizhao for raw gonadotropin collection.

IBSA generates revenue through four primary streams: sales of proprietary pharmaceutical products (largely through own subsidiaries, with licensing to multinational distributors in non-core markets), contract manufacturing for third-party pharma companies, royalties from licensed formulations and delivery technologies, and an emerging direct-to-consumer channel (IBSA Care supplements via Amazon, Yaral Pharma patches via UpScriptHealth telehealth). The go-to-market mix is sales-led through dedicated medical-scientific promotion field forces (e.g., 50 pharma reps at IBSA Italy from 2010), complemented by conference participation, retail pharmacy partnerships (Boots UK sildenafil), and digital channels. Top products include Flector Tissugel, Tirosint, Solmucol, Condrosulf, gonadotropins (Fostimon/Meriofert/Choriomon), and the water-soluble subcutaneous progesterone Lubion. IBSA is positioned among the top four global players in reproductive medicine.

Name

IBSA

Legal name

IBSA Institut Biochimique SA

Website

https://ibsagroup.com

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

IBSA is a privately held Swiss pharmaceutical company that develops and commercialises proprietary drug delivery formulations (softgel capsules, orodispersible films, hyaluronic acid injectables, gonadotropins) across 10 therapeutic areas, serving patients and healthcare professionals in 90+ countries through 20 subsidiaries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industries

Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Prescription pharmaceuticals
• Reproductive medicine drugs
• Transdermal drug delivery
• Softgel capsules manufacturing
• Hyaluronic acid injectables

Headquarters

HQ city

Lugano

HQ country

Switzerland

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Proprietary Pharmaceutical Products: IBSA develops and commercialises proprietary pharmaceutical products across 10 therapeutic areas, including reproductive medicine (gonadotropins), endocrinology (Tirosint thyroid hormones), pain/inflammation (Flector patches/gel), and aesthetic medicine (hyaluronic acid injectables), generating revenue from product sales in 90+ countries through its own subsidiaries and distribution networks.
2. Licensing and Co-development: IBSA licenses its proprietary formulations and drug delivery technologies to multinational pharmaceutical companies for distribution in markets where IBSA does not have a direct commercial presence, providing upfront fees and ongoing royalties.
3. Contract Manufacturing (CMO): IBSA operates as a contract manufacturing organisation producing injectables, softgel capsules, topical formulations, and orodispersible films for third-party pharmaceutical companies at its FDA-approved sites in Italy, Switzerland, and China.
4. Consumer Health Supplements: IBSA Care line of dietary supplements (iron orodispersible film, Vitamin D3, B12 ODF, Irosolv) sold directly to consumers via Amazon and retail channels, representing IBSA's entry into the consumer health/OTC segment.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

IBSA develops, manufactures, and commercializes proprietary pharmaceutical products across 10 therapeutic areas including reproductive medicine (gonadotropins), endocrinology (thyroid hormones), pain and inflammation (diclofenac patches), and aesthetic medicine (hyaluronic acid injectables). The company operates FDA-approved manufacturing sites in Switzerland and Italy and also markets a consumer health supplements line (IBSA Care) via e-commerce channels.

Product overview

IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical company founded in 1945, headquartered in Lugano, with products present in over 90 countries across 5 continents. Its portfolio spans 10 therapeutic areas — Reproductive Medicine, Endocrinology, Pain and Inflammation, Osteoarticular, Aesthetic Medicine, Dermatology, Uro-gynaecology, Cardiometabolic, Respiratory, and Consumer Health. The company operates across both prescription pharmaceuticals and consumer health supplements. Key pharmaceutical products include gonadotropins (Fostimon, Meriofert, Choriomon) for reproductive medicine, water-soluble subcutaneous progesterone for ART, Tirosint (levothyroxine) softgel capsules for endocrinology, Flector Tissugel (diclofenac epolamina medicated plaster) for pain/inflammation, Solmucol (N-acetylcysteine mucolytic) for respiratory conditions, Condrosulf (chondroitin sulfate) for osteoarthritis, and hyaluronic acid-based products (Ialugen, NAHYCO complexes) for aesthetic medicine and wound healing. In consumer health, IBSA markets orally dissolving film supplements (Irosolv Iron, Vitamin D3, B12) under the IBSA Care line, using proprietary FilmTec technology. The company also operates Yaral Pharma as its U.S. generics subsidiary, producing topical patches available via telehealth platforms. IBSA's product portfolio is supported by proprietary drug delivery technologies including PEARLtec (softgel capsules), NAHYCO hybrid complexes (hyaluronic acid), FilmTec orodispersible films, and BoV (Bag-on-Valve) aerosol technology.

Differentiator

Problem solved

Functional benefit

Brands

• IBSA Care: Line of dietary supplements including iron orodispersible film (Irosolv), Vitamin D3, and B12 ODF products.
• Lubion
• IBSA Foundation for children
• IBSA Foundation for scientific research
• IBSA Foundation

Products and services

• Gonadotropins (Fostimon, Meriofert, Choriomon)
• Tirosint (Levothyroxine softgel capsules)
• Flector Tissugel (diclofenac epolamine medicated plaster)
• Lubion (Progesterone) Pre-filled Syringe
• Hyaluronic Acid Products (Ialugen, NAHYCO complexes)
• Solmucol (N-acetylcysteine)
• Condrosulf (Chondroitin sulfate)
• Irosolv (IBSA Care Iron ODF)
• Yaral Pharma Topical Patches

Quantifiable outcome

• IBSA is among the top 4 companies worldwide in reproductive medicine
• +3 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• UpScriptHealthcoreChannel Partner/ Reseller/ DistributorYaral Pharma (IBSA's US generics subsidiary) made its prescription topical patches available through UpScriptHealth's national telehealth platform, enabling patients to consult with licensed clinicians online and obtain prescriptions, expanding access to affordable generic medicines through innovative digital channels.
• BootscoreChannel Partner/ Reseller/ DistributorBoots launched an own-brand sildenafil product developed with IBSA in September 2025, expanding access to erectile dysfunction treatments through UK pharmacy retail chains.
• Altergon ItaliacoreStrategic or Co-development PartnerArturo Licenziati partnered with Altergon Italia in 2011 to develop and patent an innovative biotechnological fermentation process for injectable-grade hyaluronic acid production. Altergon is now among the world's leading producers of injectable-grade hyaluronic acid.
• Università Vanvitelli (Naples)minorStrategic or Co-development PartnerIBSA collaborated with Università Vanvitelli (Prof. De Rosa and Prof. Schiraldi) to develop NAHYCO hybrid cooperative complexes of hyaluronic acid and non-sulphated biotech sodium chondroitin, as well as cooperative hybrid complexes of high and low molecular weight hyaluronic acid.
• Qingdao Huashan BiochemicalscoreStrategic or Co-development PartnerIBSA's Chinese production site, Qingdao Huashan Biochemicals, was established in 1998 through a partnership enabling the collection of urine from menopausal and pregnant women in Shandong province villages and initial processing of gonadotropin raw material. The site now spans over 5 hectares and employs approximately 100 people.

Scale indicators9 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Organon & Co. Spun off from Merck in 2021 to focus on women's health, reproductive medicine, and established brands. Directly comparable to IBSA's reproductive medicine and women's health franchises and competes in similar therapeutic categories across multiple geographies.
• Gedeon Richter Plc. Hungarian-headquartered specialty pharma with a strong women's health and reproductive medicine portfolio plus broader generics. Similar mid-sized European specialty pharma profile to IBSA, with comparable therapeutic breadth and own manufacturing footprint.
• Galderma: Global leader in dermatology and aesthetic medicine, with a major hyaluronic acid-based dermal filler franchise that directly competes with IBSA's NAHYCO/Ialugen line. Comparable scale, specialty focus, and aesthetic medicine commercial model.
• Theramex: Global specialty pharma focused on women's health, reproductive medicine, and hormone therapy. Direct competitor in fertility and endocrinology adjacencies, with similar geographic presence in Europe and emerging markets.
• Sinclair Pharma: Specialty aesthetics pharma with hyaluronic acid fillers and biostimulators — a direct competitor in IBSA's aesthetic medicine segment. Similar European specialty pharma footprint and mid-market positioning.
• Besins Healthcare: Privately held specialty pharma specializing in hormone therapies (progesterone, testosterone, oestrogen) for fertility, women's health and HRT. Closely comparable on reproductive medicine and hormone delivery focus, similar private ownership structure.
• Ferring Pharmaceuticals: Private Swiss-headquartered specialty pharma with a leading reproductive medicine portfolio (Menopur, Bravelle) competing directly with IBSA's Fostimon/Meriofert/Choriomon franchise. Closely comparable on size, geography, therapeutic focus, and vertically integrated fertility strategy.
• Merck KGaA (Healthcare/Serono fertility): Global player in fertility via its Serono heritage (Gonal-f, Pergoveris) and a top competitor in gonadotropins. Comparable on reproductive medicine and endocrinology adjacencies, though significantly larger and broader-portfolio.

Broad incumbents

• Teva Pharmaceutical Industries: Global generics leader offering transdermal patches, topical formulations, and injectables that overlap with Yaral Pharma's US generics business and IBSA's broader portfolio. Provides context for scale, pricing pressure and competitive dynamics IBSA faces in generics.

Regional players

• Aristo Pharma GmbH: German privately held specialty/generics pharma with strong presence in hormones, thyroid and pain/inflammation across DACH and broader Europe. Comparable mid-size specialty footprint and therapeutic overlap with IBSA's endocrinology and pain franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/ibsapharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries23 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IBSA